Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
NCT07795164 on ClinicalTrials.gov · last registry update 2026-08-31
An unusually large phase 3: 1,800 participants, more than double the 424 typical for the stage. Due to report December 2028, alongside 16 other tracked readouts that quarter. Primary outcome, as filed: Clinical Outcome Event. Sponsors move these dates routinely; any movement since this site started watching is listed below. pemvidutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- RECRUITING
- Phase
- P3
- Drug
- pemvidutide
- Sponsor
- Altimmune, Inc.
- Sponsor type
- Industry
- Enrollment
- 1,800
- Started
- 2026-07-30
- Primary completion
- 2028-12 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-31 | First seen in registry | Registered as RECRUITING, P3 |
Primary outcome
Clinical Outcome Event
Conditions studied
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Every field above is taken directly from the registry record. See all detected changes across the class, or the pemvidutide page for this molecule’s full trial and approval history.